Furthermore, despite skeletal muscle accounting for 80% of insulin-stimulated glucose disposal [2], and being the primary site of insulin resistance in individuals with type 2 diabetes [3], current therapies do not directly target muscle glucose disposal for therapeutic gain. This evidence concerns the gene INS and Insulin resistance.